# ORIC-944

| | |
|---|---|
| **Cat. No.:** | HY-158102 |
| **CAS No.:** | 2369769-29-7 |
| **Molecular Formula:** | $C_{26}H_{25}FN_6O$ |
| **Molecular Weight:** | 456.51 |
| **Target:** | Others |
| **Pathway:** | Others |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer. |
| **$IC_{50}$ & Target** | polycomb repressive complex 2; PRC2[1] |
| **In Vivo** | ORIC-944 (30, 100, 200 mg/kg; op; everyday for 50 days) induces significantly tumor regressions at all dose levels tested[3].<br>ORIC-944 (30 mg/kg; op; everyday for 30 days) demonstrates strong single agent activity to enzalutamide in prostate cancer xenograft model[3].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | KARPAS-422 DLBCL xenograft model[1] |
| Dosage: | 30, 100, 200 mg/kg |
| Administration: | Oral gavage (p.o.) |
| Result: | Had well tolerated at all doselevels assessed compared to tazemetostat at a clinically relevant dose. |

| | |
|---|---|
| Animal Model: | 22Rv1 model |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage (p.o.) |
| Result: | Made average tumor volume ± SEM, with n=8-10/group.<br>Had a significant difference in ORIC-944 treatment group vs vehicle. |

## REFERENCES

[1]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586.

[2]. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

[3]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models[C]//Cancer Research. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2021, 81(13).



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA